Author

T. Laitinen

Primary ORCID profile (0000-0002-7719-7783 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

T. LaitineniD1 paper

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 5 Biochemistry· 2 Biophysics· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 7 Approach:statistical model· 6 Approach:experimental assay· 5 Organism:human· 3 Research Focus:cell signaling & trafficking· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Poso· 6 shared C. R. M. Asquith· 6 shared G. J. Tizzard· 6 shared C. I. Wells· 5 shared D. H. Drewry· 3 shared G. L. Johnson· 3 shared J. M. Bennett· 3 shared J. M. Elkins· 3 shared

Activity by Year

2017-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersBiochemistry

A. Poso

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2

M. Karim, M. Mishra, C.-W. Lo, S. Saul, H. B. Cagirici, D. H. Nhu Tran, A. Agrawal, L. Ghita, A. Ojha, M. P. East, K. Anbro Gammeltoft, M. Kumar Sahoo, G. L. Johnson, S. Das, D. Jochmans, , S. Einav

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

bioRxiv · Apr 15, 2024Microbiology

Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships

C. R. M. Asquith, M. P. East, T. Laitinen, C. Alamillo-Ferrer, E. Hartikainen, C. I. Wells, A. D. Axtman, D. H. Drewry, G. J. Tizzard, A. Poso, T. M. Willson, G. L. Johnson

The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.

bioRxiv · Dec 28, 2023Pharmacology & Toxicology

Oncogenic KEAP1 mutations activate TRAF2-NFκB signaling to prevent apoptosis in lung cancer cells

A. J. Deen, S. Adinolfi, J. Harkonen, T. Patinen, X. Liu, T. Laitinen, P. Takabe, K. Kainulainen, S. Pasonen-Seppanen, L. Gawriyski, U. Thanigai Arasu, I. Selvarajan, P. Makinen, H. Laitinen, E. Kansanen, , A.-L. Levonen

This study shows that KEAP1 mutations in lung cancer activate TRAF2-NFκB signaling, enhancing cell survival by preventing apoptosis.

bioRxiv · Oct 10, 2023Cancer Biology

Structural characterization of LsrK to target quorum sensing and comparison between X-ray and homology model

P. Medarametla, T. Laitinen, A. Poso

The paper compares X-ray and homology models of LsrK to assess their reliability for structure-based drug design targeting quorum sensing.

bioRxiv · Sep 3, 2020Biophysics

Targeting the water network in cyclin G associated kinase (GAK) with 4-anilino-quin(az)oline inhibitors

C. R. M. Asquith, G. J. Tizzard, J. M. Bennett, C. I. Wells, J. M. Elkins, T. M. M. Willson, A. Poso, T. Laitinen

This paper designs and tests 4-anilinoquinoline inhibitors targeting cyclin G-associated kinase (GAK) by analyzing water networks in the ATP binding site.

bioRxiv · Mar 6, 2020Biochemistry

Identification and Optimization of cell active 4-anilino-quin(az)oline Inhibitors for Protein Kinase Novel 3 (PKN3)

C. R. M. Asquith, L. Temme, T. Laitinen, J. Pickett, F. E. Kwarcinski, P. Sinha, C. I. Wells, G. J. Tizzard, R. Zutshi, D. H. Drewry

The paper identifies 7-iodo-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine as a potent PKN3 inhibitor with an IC50 of 1.3 μM in cells, suggesting its potential as a tool for studying PKN3 biology and therapeutic applications.

bioRxiv · Mar 2, 2020 · PreprintPharmacology & Toxicology

Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships

C. R. M. Asquith, T. Laitinen, J. M. Bennett, C. I. Wells, J. M. Elkins, W. J. Zuercher, G. J. Tizzard, A. Poso

The paper designs and synthesizes 4-anilino-quin(az)oline compounds to analyze their kinase inhibition profiles and structure-activity relationships for GAK/SLK/STK10 targets.

bioRxiv · Sep 5, 2019Biochemistry

Design and evaluation of novel 4-anilinoquinolines and quinazolines as EGFR inhibitors in lung cancer and chordoma

C. R. M. Asquith, K. A. Maffuid, T. Laitinen, C. D. Torrice, G. J. Tizzard, C. Alamillo-Ferrer, K. M. Koshlap, D. J. Crona, W. Zuercher

The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.

bioRxiv · Feb 11, 2019 · PreprintPharmacology & Toxicology

Design of a GAK/EGFR inhibitor set to interrogate the relationship of EGFR and GAK in chordoma

C. Asquith, K. Naegeli, M. P. East, T. Laitinen, T. M. Havener, C. I. Wells, G. L. Johnson, D. H. Drewry, W. J. Zuercher, D. C. Morris

The paper designs a set of GAK/EGFR inhibitors to study their relationship in chordoma and characterizes their activity in vitro and through target engagement assays.

bioRxiv · Nov 20, 2018Pharmacology & Toxicology

Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase

C. R. M. Asquith, T. Laitinen, J. M. Bennett, P. H. Godoi, G. J. Tizzard, J. M. Elkins, T. M. Willson, W. J. Zuercher

The paper identifies 4-anilinoquinolines as potent GAK inhibitors with high selectivity and suggests their potential as tools for studying GAK's role in infectious diseases.

bioRxiv · Apr 11, 2017Pharmacology & Toxicology